Achmea Investment Management B.V. Has $84.36 Million Stock Position in AbbVie Inc. $ABBV

Achmea Investment Management B.V. grew its holdings in AbbVie Inc. (NYSE:ABBV) by 1.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 364,339 shares of the company’s stock after acquiring an additional 5,767 shares during the quarter. AbbVie accounts for approximately 1.0% of Achmea Investment Management B.V.’s investment portfolio, making the stock its 12th biggest position. Achmea Investment Management B.V.’s holdings in AbbVie were worth $84,359,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ABBV. Vanguard Group Inc. grew its stake in shares of AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after acquiring an additional 1,517,222 shares in the last quarter. Norges Bank acquired a new position in AbbVie in the 2nd quarter worth about $4,288,200,000. Legal & General Group Plc increased its holdings in AbbVie by 4.3% in the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock worth $2,779,426,000 after purchasing an additional 493,420 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 5.1%

Shares of AbbVie stock opened at $208.47 on Thursday. The business has a 50-day moving average price of $223.76 and a two-hundred day moving average price of $224.84. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a market cap of $368.62 billion, a P/E ratio of 88.34, a PEG ratio of 0.76 and a beta of 0.34.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the company earned $2.16 EPS. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year collaboration with AbbVie to advance a next‑generation antibody discovery platform, providing upfront and milestone payments and potential pipeline upside. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: Legendary investor Ken Fisher has AbbVie among notable portfolio moves for 2026, signaling continued institutional interest that can support the stock over the medium term. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Positive Sentiment: Zacks highlights AbbVie as a strong value pick based on style scores and fundamentals, which may attract value-oriented buyers amid short‑term weakness. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: Technically, ABBV slipped below its 50‑day moving average, signaling short‑term weakness to traders but it remains above the 200‑day average, so the long‑term trend is intact. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
• Neutral Sentiment: Market commentary (MSN/Benzinga) notes the share move largely reflects competitor progress rather than new AbbVie-specific fundamentals—useful for context but not new company data. What’s Going On With AbbVie Stock Today?
• Neutral Sentiment: High‑level policy reporting shows TrumpRx price lists aren’t uniformly cheaper than the UK, a reminder of ongoing pricing and regulatory scrutiny in pharma but not an AbbVie‑specific action today. TrumpRx lists many medicines at prices higher than paid in UK
• Negative Sentiment: FDA approved J&J’s oral IL‑23 inhibitor (Icotyde), the first oral peptide that blocks IL‑23 and a direct competitive threat to Skyrizi/Tremfya; J&J expects this class could reach blockbuster sales, increasing pressure on AbbVie’s pricing and market share in psoriasis. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: several outlets report ABBV shares fell sharply today after the J&J approval, indicating investor concern about near‑term revenue impact for Skyrizi. AbbVie (ABBV) Shares Plunge Nearly 5% as FDA Clears J&J’s Rival Psoriasis Treatment
• Negative Sentiment: Legal risk: a U.S. appeals court revived a whistleblower suit accusing big drugmakers of overcharging programs for low‑income patients, reviving potential litigation and settlement exposure for major pharma names. Big drugmakers must face US overcharge claims on medications for low-income patients

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ABBV shares. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Citigroup reduced their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Berenberg Bank set a $275.00 price objective on AbbVie in a report on Tuesday, January 20th. UBS Group cut their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Finally, Royal Bank Of Canada initiated coverage on AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.